First Report of Trametinib‐Nintedanib Combination in <scp>KRAS G12D</scp> ‐Mutated Pancreatic Cancer: Efficacy and Fatal Hemorrhagic Complication: A Case Report
This is the first report of trametinib-nintedanib for a 57-year-old KRAS G12D-mutated recurrent pancreatic ductal adenocarcinoma. He had transient remission (lower CA19-9, stable lesions) but died of gastrointestinal bleeding, showing efficacy and bleeding risk.
Authors
- Song Wang (ORCID: https://orcid.org/0000-0002-4476-1915)
- Yuan Li (ORCID: https://orcid.org/0000-0002-5186-6360)
- Yufei Zhao (ORCID: https://orcid.org/0000-0002-1662-231X)
- Chensi Wu (ORCID: https://orcid.org/0000-0002-9048-7558)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1002/ccr3.71505
- Citations
- 1
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05